Silence Therapeutics plc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Silence Therapeutics plc (SLN) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $18.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- Silence Therapeutics plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $18.97M.
- Silence Therapeutics plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$2.29M, a 212.62% decline from fiscal 2023.
- Silence Therapeutics plc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.04M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $18.97M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$2.29M 10-K · filed 2026-03-05 |
| 2023-12-31 | $2.04M 10-K · filed 2025-02-27 |